Suppr超能文献

纤溶酶原激活剂与癌症

Plasminogen activators and cancer.

作者信息

Duffy M J

机构信息

Nuclear Medicine Department, St Vincent's Hospital, Dublin, Republic of Ireland.

出版信息

Blood Coagul Fibrinolysis. 1990 Dec;1(6):681-7.

PMID:2133247
Abstract

Plasminogen activator (PA) is a specific serine protease which catalyses conversion of the inactive plasminogen into the broad-spectrum protease, plasmin. PA exists in two structurally related forms known as tissue-type PA (tPA) and urokinase-type PA (uPA). Conversion of normal cells into a malignant state frequently leads to increased production of uPA. There is increasing evidence that uPA is directly involved in the process of metastasis. High levels of uPA in human breast cancers is a marker for poor prognosis. Finally, uPA may be a target for anti-metastatic agents, either by inhibition of its synthesis, inhibition of its activity or its binding to receptor.

摘要

纤溶酶原激活剂(PA)是一种特异性丝氨酸蛋白酶,它催化无活性的纤溶酶原转化为广谱蛋白酶——纤溶酶。PA以两种结构相关的形式存在,即组织型PA(tPA)和尿激酶型PA(uPA)。正常细胞转变为恶性状态常常导致uPA产生增加。越来越多的证据表明,uPA直接参与转移过程。人类乳腺癌中高水平的uPA是预后不良的一个标志物。最后,uPA可能是抗转移药物的一个靶点,可通过抑制其合成、抑制其活性或抑制其与受体的结合来实现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验